KMID : 0363220230610050265
|
|
Korean Journal of Dermatology 2023 Volume.61 No. 5 p.265 ~ p.274
|
|
Guselkumab Treatment for Psoriasis in Bio-Naive and Bio-Experienced Patients: Multicenter Study Based on a 1-Year Follow-Up
|
|
Oh Seon-A
Lee Su-Min Ko Byeong-Chang Seol Jung-Eun Lee Un-Ha Kim Myoung-Shin Jung So-Yeong Oh Min-Kyung Park Hai-Jin
|
|
Abstract
|
|
|
Background: Guselkumab is a monoclonal antibody that selectively blocks the p19 subunit of interleukin-23. It has shown good efficacy and safety profile in several clinical trials of plaque psoriasis. However, studies on the efficacy of guselkumab in patients treated with other biologics are lacking.
Objective: We aimed to investigate the efficacy and safety profile of guselkumab in patients with moderate-to-severe plaque psoriasis. We also compared the efficacy of guselkumab between biologic-naive (Bio-Naive) and biologic- experienced (Bio-Ex) patients.
Methods: This multicenter, retrospective study included 72 patients treated with guselkumab. The patients¡¯ clinical characteristics and psoriasis area and severity index (PASI) scores were recorded at each visit. The PASI90 and PASI100 responses and mean PASI scores were compared between the Bio-Naive and Bio-Ex groups.
Results: Fifty-five Bio-Naive patients and 17 Bio-Ex patients were included in the study. At week 20, there were no significant differences in the PASI90 (64.2% vs. 53.8%) and PASI100 (28.3% vs. 15.4%) responses between the groups.
However, at weeks 36 and 44, the PASI90 response (week 36: 89.2% vs. 36.4% and week 44: 97.8% vs. 63.6%) and the PASI100 response (week 36: 64.9% vs. 18.2% and week 44: 68.9% vs. 27.3%) were significantly higher in the Bio-Naive group (p£¼0.05). There were no differences in PASI90 and PASI100 responses between the groups in terms of other clinical characteristics and comorbidities at week 20.
Conclusion: The efficacy of guselkumab remained consistent among patients in whom other biologics had failed.
However, the efficacy was slightly lower in the Bio-Ex group than in the Bio-Naive group.
|
|
KEYWORD
|
|
Biological product, Guselkumab, Psoriasis, Treatment switching
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|